Amy Pott

Amy Pott is an experienced executive in the pharmaceutical and biotechnology sectors, currently serving as the Chief Global Commercialization Officer at enGene since May 2025. Prior to this role, Amy held significant positions at Astellas Pharma, including Head of Ophthalmics and Rare Disease, Global Commercial, and Head of Commercial for Astellas Gene Therapies from January 2021 to May 2025. Additional experience includes serving as a Board Member at Wave Life Sciences, Head of North America at Sobi - Swedish Orphan Biovitrum AB, and various leadership roles at Shire, Baxalta Inc., and Baxter. Amy began professional experience in corporate communications with the National Institute for Health and Clinical Excellence. Educational background includes studies at The London School of Economics and Political Science.